Auriculo-condylar syndrome
|
0.620 |
Biomarker
|
disease |
BEFREE |
In order to address these questions, we searched for alterations in PLCB4, GNAI3, and EDN1 in patients with typical Auriculocondylar syndrome (n = 3), Pierre Robin sequence-plus (n = 3), micrognathia with additional craniofacial malformations (n = 4), or non-specific auricular dysplasia (n = 1), which could represent subtypes of Auriculocondylar syndrome.
|
28328130 |
2017 |
Auriculo-condylar syndrome
|
0.620 |
GermlineCausalMutation
|
disease |
ORPHANET |
These findings provide further support for the hypothesis that ACS and QMEs are uniquely caused by disruption of the EDN1-EDNRA signaling pathway.
|
24268655 |
2013 |
Auriculo-condylar syndrome
|
0.620 |
GeneticVariation
|
disease |
BEFREE |
Mutations in endothelin 1 cause recessive auriculocondylar syndrome and dominant isolated question-mark ears.
|
24268655 |
2013 |
Auriculo-condylar syndrome
|
0.620 |
Biomarker
|
disease |
CTD_human |
|
|
|
Auriculo-condylar syndrome
|
0.620 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Auriculocondylar syndrome 1
|
0.610 |
GeneticVariation
|
disease |
BEFREE |
Auriculocondylar syndrome and isolated question mark ear result from dysregulation of the endothelin 1-endothelin receptor type A signaling pathway.
|
28456137 |
2018 |
Auriculocondylar syndrome 1
|
0.610 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in endothelin 1 cause recessive auriculocondylar syndrome and dominant isolated question-mark ears.
|
24268655 |
2013 |
Auriculocondylar syndrome 1
|
0.610 |
Biomarker
|
disease |
HPO |
|
|
|
Auriculocondylar syndrome 1
|
0.610 |
Biomarker
|
disease |
CTD_human |
|
|
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension.
|
31514181 |
2020 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 has been studied as a predictor of and prognostic marker in coronary artery disease, myocardial infarction, and heart failure.
|
30765295 |
2020 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lower risk for heart failure with higher ET1 levels could not be clearly shown in a model including health behaviors.
|
31515065 |
2020 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension.
|
31514181 |
2020 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 has been studied as a predictor of and prognostic marker in coronary artery disease, myocardial infarction, and heart failure.
|
30765295 |
2020 |
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lower risk for heart failure with higher ET1 levels could not be clearly shown in a model including health behaviors.
|
31515065 |
2020 |
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
We assessed the role of endothelin-1, acting through endothelin A (ET<sub>A</sub> ) receptors, in modulating the central and peripheral cardiovascular responses to exercise in patients with hypertension via local antagonism of these receptors during exercise.
|
31705661 |
2020 |
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Opposite alterations of endothelin-1 in lung and pulmonary artery mirror gene expression of bone morphogenetic protein receptor 2 in experimental pulmonary hypertension.
|
31012341 |
2020 |
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension.
|
31514181 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.600 |
Biomarker
|
disease |
BEFREE |
Individuals with T2DM show a misbalance between the synthesis, release, and biological actions of vasodilators and vasoconstrictors such as nitric oxide and endothelin-1.
|
30849412 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting the EC-Foxp1-TGF-β1-endothelin-1 pathway might provide a future novel therapy for heart failure.
|
31177814 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results revealed that TCDD directly induces cardiotoxicity in the postnatal period represented by progressive hypertrophy in which ANP, β-MHC, and ET-1 have potentials to mediate the cardiac hypertrophy and heart failure.
|
31270306 |
2019 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting the EC-Foxp1-TGF-β1-endothelin-1 pathway might provide a future novel therapy for heart failure.
|
31177814 |
2019 |
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results revealed that TCDD directly induces cardiotoxicity in the postnatal period represented by progressive hypertrophy in which ANP, β-MHC, and ET-1 have potentials to mediate the cardiac hypertrophy and heart failure.
|
31270306 |
2019 |
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide considered to be causally implicated in hypertension and the development of cardiovascular disease.
|
31630572 |
2019 |
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Endothelin-1 (ET-1), as it functions as a neuromodulator, has been associated with hypertension in chronic intermittent hypoxia (CIH) which attribute to enhanced carotid body sensibility to hypoxia.
|
30579678 |
2019 |